John Goheen

John Goheen is a partner in Goodwin’s Antitrust and Competition practice and Complex Litigation & Dispute Resolution practice. He advises clients on matters involving all aspects of antitrust and competition law, including merger reviews, government antitrust investigations, antitrust litigation, and counseling on a variety of competition issues. He regularly represents clients in antitrust investigations by the FTC, DOJ, and state attorneys general, and has experience counseling clients across a wide range of industries, including technology, healthcare, pharmaceuticals, financial services, consumer products, retail, infrastructure, industrials and manufacturing, and business and professional services.

In addition, John regularly advises healthcare clients regarding state “mini-HSR” filing requirements, which are a rapidly developing area of competition law. He counsels clients regarding preliminary mini-HSR filing analyses and exemptions, assists with all phases of the filing process, and advocates before state AGs and state healthcare regulatory bodies.

John’s representative experience includes advising:

• Enfusion in its $1.5 billion acquisition by Clearwater Analytics
• Brightcove in its $233 million acquisition by Bending Spoons 
• Aerovate Therapeutics in its definitive merger agreement to combine with Jade Biosciences in an all-stock transaction
• Versanis Bio in its definitive agreement to be acquired by Eli Lilly and Company for up to $1.925 billion
• Bobbie in its acquisition of Nature’s One
• Qualtrics International in its acquisition by Silver Lake, in partnership with CPP Investments, for approximately $12.5 billion
• PPD in its $17.4 billion acquisition by Thermo Fisher Scientific*
• Melrose in its $3.625 billion sale of Nortek Air Management Business to Madison Industries*
• Hellman & Friedman in its acquisition of The NPD Group*
• BMC Stock Holdings in its merger with Builders FirstSource*
• Renaissance Learning in its acquisition of myON*
• Lorillard in the FTC review and clearance of its $27.4 billion sale to Reynolds American*
• K2M in its $1.4 billion acquisition by Stryker*
• Mars in its acquisition of KIND North America*
• Applied Systems in its acquisition of Indio Technologies*
• HCA in its simultaneous acquisitions of several hospitals from Tenet Health and Community Health Systems in Houston, TX*

*Denotes experience prior to joining Goodwin

John serves on the board for the Lutheran Social Services of the National Capital Association (“LSSNCA”), a DC-based social services organization focusing on refugee and immigrant resettlement, workforce development programs, family and children services, and health, wellness, and education services.

Prior to joining Goodwin, John was counsel at Simpson Thacher & Bartlett.

• Merger Control, Legal 500 US, 2024-2025
• 40 & Under Hot List, Benchmark Litigation, 2024-2025
• One to Watch in Antitrust Law, The Best Lawyers in America, 2021-2023
• Future Leader (2019-2022) and Highest Ranked Lawyers Competition (2023-2024), Who’s Who Legal
• Capital Pro Bono Honor Roll, District of Columbia Courts, 2020-2022

John’s publications include:

• Co-Author, “Oregon Governor Signs Law Aggressively Restricting Private Equity Investment in Medical Practices,” Goodwin Client Alert, June 11, 2025
• Co-author, “Oregon on the Verge of Restricting Private Equity Investment in Medical Practices,” Goodwin Client Alert, May 30, 2025
• Co-author, “Antitrust & Competition Healthcare Quarterly Update Q1 2025,” Goodwin Client Alert, May 13, 2025
• Co-author, “Washington Becomes First State to Adopt Filing Requirements for HSR-Reportable Transactions Outside of Healthcare,” Goodwin Client Alert, April 24, 2025
• Co-Author, “States Continue to Pursue and Expand Healthcare Market Oversight at an Unprecedented Pace, With Significant Implications for Private Equity,” Goodwin Client Alert, March 20, 2025
• Co-Author, “FTC’s First Merger Challenge Under New Leadership Signals Return to Traditional Antitrust Theories in Private Equity Deals,” Goodwin Client Alert, March 12, 2025
• Co-Author, “DOJ Sues Private Equity Firm KKR & Co. for Violations of HSR Act,” Goodwin Client Alert, January 16, 2025
• Co-Author, “Massachusetts Passes Comprehensive Revisions to Healthcare Transaction Notification Law with Significant Implications for Private Equity Healthcare Investments,” Goodwin Client Alert, January 14, 2025
• Co-Author, “Business Groups File Lawsuit Challenging HSR Rule Changes,” Goodwin Client Alert, January 13, 2025
• Co-Author,” Governor Nixes bill on Private Equity in California Healthcare (Los Angeles & San Francisco Daily Journal),”In the Press, November 7, 2024
• Co-author, “FTC Escalates Battle Against PBMs With Complaint on Insulin Pricing,” Goodwin Client Alert, October 1, 2024
• Co-author, “Governor Vetoes California Assembly Bill 3129, Regulating Private Equity- and Hedge Fund-backed Healthcare Transactions,” Goodwin Client Alert, September 30, 2024
• Co-author, “Antitrust & Competition Healthcare Quarterly Update Q2 2024,” Antitrust Trends in Technology, Life Sciences, and Healthcare, September 18, 2024
• Co-author, “Five Steps Hotel Owners, Operators, and Management Companies Can Take to Mitigate Risk in the Face of Heightened Antitrust Scrutiny and a Wave of Lawsuits Involving Revenue-Management Tools,” Hospitality & Leisure Trend Watch, September 12, 2024
• Co-author, “California Assembly Bill 3129, Regulating Private Equity- and Hedge Fund-backed Healthcare Transactions, Awaiting Governor’s Approval,” Goodwin Client Alert, September 5, 2024
• Co-author, “Federal Court Preliminarily Enjoins Enforcement of the FTC Non-Compete Rule, but Only for the Plaintiffs: What Are the Implications for All Other Employers?” Goodwin Client Alert, July 8, 2024
• Co-author, “State Healthcare Transaction Notification Laws: State-by-State Regulatory Review,” Goodwin Resource, June 13, 2024
• Co-author, “Indiana Enacts Broad Notification Requirements for Healthcare Transactions with a Clear Focus on Private Equity,” Goodwin Client Alert, May 20, 2024
• Co-author, “District Court Grants Welsh Carson’s Motion to Dismiss in FTC’s “Roll-Up” Monopolization Case; Case Against U.S. Anesthesia Partners Continues,” Goodwin Client Alert, May 15, 2024
• Co-author, “FTC Issues Final Rule Prohibiting Most Post-Employment Non-Compete Agreements,” Goodwin Client Alert, April 25, 2024
• Co-author, “FTC and DOJ Launch New Cross-Government Inquiry on the Role of Private Equity in Healthcare,” Goodwin Client Alert, March 7, 2024
• Co-author, “US Antitrust Agencies Release Final Revised Merger Guidelines,” Goodwin Client Alert, December 19, 2023
• Co-author, “FTC Sues Private Equity Firm Welsh Carson and U.S. Anesthesia Partners Over Alleged Anesthesiology ‘Roll-Up Scheme’ in Texas,” Goodwin Client Alert, September 22, 2023
• Co-author, “US Antitrust Regulators Continue to Crack Down on Interlocking Directorates, and the FTC Expands Scope of Clayton Act to Noncorporate Entities,” Goodwin Client Alert, August 25, 2023
• Co-author, “US Antitrust Agencies Release Revised Draft Merger Guidelines,” Goodwin Client Alert, July 20, 2023
• Co-author, “FTC and DOJ Propose Major Changes to HSR Form and Disclosure,” Goodwin Client Alert, June 28, 2023

John’s speaking engagements include:

• Speaker, “PE Implications of Recent Revisions to Massachusetts' Healthcare Transaction Review Law,” Goodwin Webinar, March 11, 2025
• Speaker, “The Evolving Landscape of Client Advocacy in Second Request Reviews,” TransPerfect Legal Antitrust Clearance & Merger Enforcement Conference, October 10, 2024
• Speaker, “The Future of Non-Compete Agreements in America,” Goodwin Webinar, June 27, 2024
• Speaker, “Antitrust Implications of State Regulators’ Increasing Scrutiny,” Goodwin Webinar, June 13, 2024